Raleigh Capital Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Raleigh Capital Management’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-257	Closed	-$23.3K	–	1013
2024 Q1	$23.3K	Hold	257	–	–	0.01%	403
2023 Q4	$20.9K	Buy	+257	New	+$20.2K	0.01%	429
2023 Q3	–	Sell	-258	Closed	-$20.8K	–	943
2023 Q2	$20.3K	Buy	258 +2	+0.8%	+$157	0.01%	387
2023 Q1	$19.9K	Hold	256	–	–	0.01%	374
2022 Q4	$19.9K	Buy	256 +2	+0.8%	+$148	0.01%	319
2022 Q3	$17K	Buy	254 +1	+0.4%	+$74	0.01%	303
2022 Q2	$19K	Buy	253 +1	+0.4%	+$78	0.01%	299
2022 Q1	$20K	Buy	+252	New	+$19.3K	0.01%	295

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCIA

Prime Capital Investment Advisors Overland Park, Kansas $8.65B AUM 19.52% 1-Year Est. Return

FPGK

Financial Partners Group (Kansas) Overland Park, Kansas $836M AUM 21.04% 1-Year Est. Return

Raleigh Capital Management's PPH Position: Q2 2024 in Review

Raleigh Capital Management sold out of VanEck Pharmaceutical ETF (PPH) in Q2 2024, closing a stake of 257 shares — an estimated $23.3K sold.

Raleigh Capital Management first reported a position in PPH in Q1 2022 and held it in 8 quarters. The position peaked at $23.3K in Q1 2024. 140 funds tracked by Wall St. Rank hold PPH as of Q2 2024.

Raleigh Capital Management reported no remaining VanEck Pharmaceutical ETF position as of Q2 2024 after selling out during the quarter.
Raleigh Capital Management sold 257 VanEck Pharmaceutical ETF shares in Q2 2024, an estimated $23.3K.
Raleigh Capital Management first reported a position in VanEck Pharmaceutical ETF in Q1 2022 and held it in 8 quarters.
Raleigh Capital Management's VanEck Pharmaceutical ETF position peaked at $23.3K in Q1 2024.
140 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2024.

Based on Raleigh Capital Management's 13F filing for Q2 2024, filed 31 Jul 2024.